New Trade Alert: OncoSec Medical Incorporated (NASDAQ: ONCS)
A Little About ONCS:
“OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12.
In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response.
ImmunoPulse® IL-12, OncoSec’s lead program, is currently in clinical development for metastatic melanoma and triple-negative breast cancer.
The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies.
In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform.”
ONCS released breaking news this morning that may provide an additional catalyst for upside potential.
OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors
Former President and CEO of Advaxis Immunotherapies and Senior Vice President of ImClone Systems adds significant biopharma clinical, regulatory, business development, and fundraising expertise to OncoSec
SAN DIEGO, Sept. 7, 2017 /PRNewswire/ — OncoSec Medical Incorporated “OncoSec” (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Daniel J. O’Connor to its Board of Directors. Mr. O’Connor brings more than 20 years of successful financing and licensing experience to OncoSec’s Board of Directors, most recently serving as President and Chief Executive Officer of Advaxis Immunotherapies. His appointment to the Company’s Board is effective immediately.
“Dan is a proven leader with a strong track record of success. He brings exceptional strategic and operational expertise in building thriving, successful biopharma companies, and we are pleased to welcome Dan to the Board,” said Punit Dhillon, President and CEO of OncoSec. “His history with commercializing and licensing cancer immunotherapy products will be vital as we continue to progress our lead melanoma program through clinical trials and registration.”
“OncoSec’s ImmunoPulse® IL-12 clinical program in melanoma and broader pipeline have the potential to address significant unmet needs for cancer patients with few or no treatment options,” said Mr. O’Connor. “I am excited about the potential therapeutic opportunity to combine with and enhance the existing success of the checkpoint inhibitor class of compounds. I believe that OncoSec has the leading platform to address late stage relapsed or refractory solid tumors and look forward to contributing to the advancement of the Company’s exciting portfolio.”
Most recently, as President and Chief Executive Officer of Advaxis Immunotherapies, Mr. O’Connor successfully turned around the company, raising more than $250 million in funding and transforming it into a patient-focused, leading cancer immunotherapy company. He was also instrumental in establishing major partnerships with companies that include Amgen Inc., Merck & Co. and Bristol Myers Squibb. In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda® and Opdivo®. Previously, Mr. O’Connor was Senior Vice President for ImClone Systems where he supported the clinical development, launch, and commercialization of ERBITUX®, and the sale of the company to Eli Lilly in 2008. Mr. O’Connor served as General Counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew the company from a start-up contract research organization into a leader in clinical research. Mr. O’Connor is a 1995 graduate of the Penn State University’s Dickinson School of Law in Carlisle, Pennsylvania and currently serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as an officer in the U.S. Marines, attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Mr. O’Connor is currently the Vice Chairman of BioNJ and was a former New Jersey criminal prosecutor.
Source: Yahoo Finance
OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences
SAN DIEGO, Sept. 6, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be presenting at several events in September, including:
- Rodman & Renshaw 18thAnnual Global Investment Conference
- Johnson & Johnson Innovation + JLABS Science 1stSpeaking Series
- Phacilitate Cell & Gene Therapy Europe 2017
- 2ndWorld Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Rodman & Renshaw 18th Annual Global Investment Conference
Punit Dhillon, OncoSec’s Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference on September 11th at 10:25 AM ET at The Lotte New York Palace Hotel in New York City.
OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors
Former Head of Global Research and Development for Merck Serono and Head of Global Medical Affairs of Bristol-Myers Squibb brings biopharma drug development, fundraising and M&A experience to OncoSec
SAN DIEGO, Sept. 5, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company” (ONCS)), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of Annalisa Jenkins, MBBS, FRCP, CEO of Dimension Therapeutics, Inc. (DMTX), to its Board of Directors. Dr. Jenkins brings over 25 years of global industry experience to OncoSec’s Board of Directors with a wealth of knowledge in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Her election to the Company’s Board is effective immediately.
“We are very pleased to have Dr. Jenkins join our Board as we believe her international biopharma drug development experience will be an asset to OncoSec as we advance our lead melanoma program and pursue collaborations with other industry leaders in oncology,” said Punit Dhillon, President and CEO of OncoSec. “Drawing on her years of experience in the biopharma industry, we believe Dr. Jenkins will provide new insights to our technology and business priorities as we continue to advance our broad clinical portfolio and achieve future growth objectives.”
“I believe OncoSec’s clinical program for ImmunoPulse® IL-12 can have a significant impact on how we approach cancer care by addressing a significant unmet need for melanoma patients that do not currently respond to anti-PD-1 treatments. In addition, I’m impressed with the Company’s commitment to advancing its innovative drug development approach, putting science and patients at the core of its mission,” said Dr. Jenkins. “I look forward to contributing to the Company’s advancement of its promising product candidates through clinical development.”
Prior to Dimension Therapeutics, Dr. Jenkins served as Executive Vice President and Head of Global Research and Development for Merck Serono, a global division of Merck KGaA focused on biopharmaceuticals. She also led Global Medical Affairs and Quality at Merck Serono and was a member of its Pharmaceutical Executive Committee. Dr. Jenkins also had a nearly 15-year career at Bristol-Myers Squibb, attaining the role of Senior Vice President and Head of Global Medical Affairs. She began her career as a Medical Officer with the British Royal Navy during the Gulf conflict, rising to the rank of Surgeon Lieutenant Commander. Dr. Jenkins received an MBBS in Medicine from St. Bartholomew’s Hospital in the University of London and trained in cardiovascular medicine in the National Health Service (U.K.).
Currently, Dr. Jenkins serves as a director for several companies including: Ardelyx, Inc., Biothera Pharmaceutical Inc., iOX Therapeutics Limited, MedCity and Vium. She also is a committee member of the Science Board to the U.S. Food and Drug Administration, serves on the Board of the Center for Talent Innovation (U.K.) and is on the Advisory Panel of the Healthcare Businesswomen’s Association.
We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term trade opportunities.
We have received five thousand dollars via a bank wire for the awareness of ONCS.
Any type of reproduction, copying or distribution of the material in this email is prohibited without a written consent from the site owner.
All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.